Trials / Completed
CompletedNCT01420055
Fingolimod -Response According to Coping - Evaluation
A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, multi-center phase IV study to assess response to fingolimod initiation according to coping profile in adult patients with highly active relapsing remitting multiple sclerosis in France.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fingolimod |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2011-08-19
- Last updated
- 2016-11-18
Locations
47 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01420055. Inclusion in this directory is not an endorsement.